Skip to main content
Have a personal or library account? Click to login
SEM/EDS analysis as a complementary tool for continuous improvement of cefixime granules for oral suspension Cover

SEM/EDS analysis as a complementary tool for continuous improvement of cefixime granules for oral suspension

Open Access
|Jun 2026

References

  1. International Council for Harmonisation, ICH Harmonised Guideline Q8(R2): Pharmaceutical Development, Current Step 4 version, August 2009; https://database.ich.org/sites/default/files/Q8_R2_Guideline.pdf; last access date May 27, 2026.
  2. International Council for Harmonisation, ICH Harmonised Guideline Q9(R1): Quality Risk Management, Current Step 4 version, 18 January 2023; https://database.ich.org/sites/default/files/ICH_Q9%28R1%29_Guideline_Step4_2022_1219.pdf; last access date May 27, 2026.
  3. International Council for Harmonisation, ICH Harmonised Tripartite Guideline Q10: Pharmaceutical Quality System, Current Step 4 version, 4 June 2008; https://database.ich.org/sites/default/files/Q10%20Guideline.pdf; last access date May 27, 2026.
  4. Food and Drug Administration, Process Validation: General Principles and Practices, Guidance for Industry, January 2011; https://www.fda.gov/files/drugs/published/Process-Validation-General-Principles-and-Practices.pdf; last access date May 27, 2026.
  5. Food and Drug Administration, PAT – A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance, Guidance for Industry, September 2004; https://www.fda.gov/media/71012/download; last access date May 27, 2026.
  6. International Council for Harmonisation, ICH Harmonised Guideline Q14: Analytical Procedure Development, Final version, adopted on 1 November 2023; https://database.ich.org/sites/default/files/ICH_Q14_Guideline_2023_1116_1.pdf; last access date May 27, 2026.
  7. International Council for Harmonisation, ICH Harmonised Tripartite Guideline Q1A(R2): Stability Testing of New Drug Substances and Products, Current Step 4 version, 6 February 2003; https://database.ich.org/sites/default/files/Q1A%28R2%29%20Guideline.pdf; last access date May 27, 2026.
  8. S. M. Iveson, J. D. Litster, K. Hapgood and B. J. Ennis, Nucleation, growth and breakage phenomena in agitated wet granulation processes: A review, Powder Technol. 117(1–2) (2001) 3–39; https://doi.org/10.1016/S0032-5910(01)00313-8
  9. J. D. Litster and B. J. Ennis, The Science and Engineering of Granulation Processes, Kluwer Academic Publishers, Dordrecht 2004; https://doi.org/10.1007/978-94-017-0546-2
  10. D. M. Parikh (Ed.), Handbook of Pharmaceutical Granulation Technology, 3rd ed., CRC Press, Boca Raton 2016; https://doi.org/10.3109/9781616310035
  11. M. E. Aulton and K. M. G. Taylor (Eds.), Aulton’s Pharmaceutics: The Design and Manufacture of Medicines, 5th ed., Elsevier, Edinburgh 2018.
  12. P. J. Sheskey, W. G. Cook and C. G. Cable (Eds.), Handbook of Pharmaceutical Excipients, 9th ed., Pharmaceutical Press, London 2020.
  13. H. G. Brittain (Ed.), Physical Characterization of Pharmaceutical Solids, Marcel Dekker, New York 1995.
  14. S. R. Byrn, R. R. Pfeiffer and J. G. Stowell, Solid-State Chemistry of Drugs, 2nd ed., SSCI, West Lafayette 1999.
  15. B. C. Hancock and G. Zografi, Characteristics and significance of the amorphous state in pharmaceutical systems, J. Pharm. Sci. 86(1) (1997) 1–12; https://doi.org/10.1021/js9601896
  16. J. I. Goldstein, D. E. Newbury, J. R. Michael, N. W. M. Ritchie, J. H. J. Scott and D. C. Joy, Scanning Electron Microscopy and X-ray Microanalysis, 4th ed., Springer, New York 2018; https://doi.org/10.1007/978-1-4939-6676-9
  17. P. J. Goodhew, J. Humphreys and R. Beanland, Electron Microscopy and Analysis, 3rd ed., Taylor & Francis, London 2000; https://doi.org/10.1201/9781482289343
  18. P. Echlin, Handbook of Sample Preparation for Scanning Electron Microscopy and X-ray Microanalysis, Springer, New York 2009; https://doi.org/10.1007/978-0-387-85731-2
  19. D. E. Newbury and N. W. M. Ritchie, Is scanning electron microscopy/energy dispersive X-ray spectrometry (SEM/EDS) quantitative?, Scanning 35(3) (2013) 141–168; https://doi.org/10.1002/sca.21041
  20. D. E. Newbury and N. W. M. Ritchie, Electron-excited X-ray microanalysis by energy dispersive spectrometry at 50: Analytical accuracy, precision, trace sensitivity, and quantitative compositional mapping, Microsc. Microanal. 25(5) (2019) 1075–1105; https://doi.org/10.1017/S143192761901482X
  21. R. N. Brogden and D. M. Campoli-Richards, Cefixime: A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential, Drugs 38(4) (1989) 524–550; https://doi.org/10.2165/00003495-198938040-00004
  22. S. R. El-Shaboury, G. A. Saleh, F. A. Mohamed and A. H. Rageh, Analysis of cephalosporin antibiotics, J. Pharm. Biomed. Anal. 45(1) (2007) 1–19; https://doi.org/10.1016/j.jpba.2007.06.002
  23. A. D. Deshpande, K. G. Baheti and N. R. Chatterjee, Degradation of β-lactam antibiotics, Curr. Sci. 87(12) (2004) 1684–1695.
  24. K. C. Waterman and R. C. Adami, Accelerated aging: Prediction of chemical stability of pharmaceuticals, Int. J. Pharm. 293(1–2) (2005) 101–125; https://doi.org/10.1016/j.ijpharm.2004.12.013
  25. Z. Talebpour, H. Pourabdollahi, H. Rafati, A. Abdollahpour, Y. Bashour and H. Y. Aboul-Enein, Determination of cefixime by a validated stability-indicating HPLC method and identification of its related substances by LC-MS/MS studies, Sci. Pharm. 81(2) (2013) 493–503; https://doi.org/10.3797/scipharm.1301-15
  26. S. P. Gandhi and S. J. Rajput, Study of degradation profile and development of stability indicating methods for cefixime trihydrate, Indian J. Pharm. Sci. 71(4) (2009) 438–442; https://doi.org/10.4103/0250-474X.57295
  27. S. Yu, Y. Zhang and X. Z. Wang, Improved understanding of cefixime trihydrate reactive crystallization and process scale-up with the aid of PAT, Org. Process Res. Dev. 23(2) (2019) 177–188; https://doi.org/10.1021/acs.oprd.8b00190
  28. Y. Roggo, P. Chalus, L. Maurer, C. Lema-Martinez, A. Edmond and N. Jent, A review of near infrared spectroscopy and chemometrics in pharmaceutical technologies, J. Pharm. Biomed. Anal. 44(3) (2007) 683–700; https://doi.org/10.1016/j.jpba.2007.03.023
  29. G. Reich, Near-infrared spectroscopy and imaging: Basic principles and pharmaceutical applications, Adv. Drug Deliv. Rev. 57(8) (2005) 1109–1143; https://doi.org/10.1016/j.addr.2005.01.020
  30. T. Vankeirsbilck, A. Vercauteren, W. Baeyens, G. Van der Weken, F. Verpoort, G. Vergote and J. P. Remon, Applications of Raman spectroscopy in pharmaceutical analysis, TrAC Trends Anal. Chem. 21(12) (2002) 869–877; https://doi.org/10.1016/S0165-9936(02)01208-6
DOI: https://doi.org/10.2478/acph-2026-0018 | Journal eISSN: 1846-9558 | Journal ISSN: 1330-0075
Language: English
Page range: 1 - 11
Accepted on: Jun 10, 2026
Published on: Jun 30, 2026
In partnership with: Paradigm Publishing Services
Related subjects:

© 2026 Ivana Mitrevska, Dino Karpicarov, Ana Mihailovska, Dejan Mirakovski, Olivera Paneva, Gjorgji Petrushevski, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.